Baird raised the firm’s price target on Boston Scientific (BSX) to $128 from $123 and keeps an Outperform rating on the shares. The firm said they remain buyers of the shares following its investor day which increased conviction in its premium growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $132 from $131 at Canaccord
- Boston Scientific’s Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Promising Growth Trajectory: A Buy Rating Backed by Strong Financial Targets and Key Franchises
- Boston Scientific’s Promising Growth Trajectory: Buy Rating Supported by Innovative Products and Strategic Expansion
- Strong Buy Rating for Boston Scientific: Promising Growth and Profitability Outlook